

**iCare** ILLUME



**Instant detection of  
vision-threatening eye diseases  
using artificial intelligence**

For better perception **icare**

# iCare ILLUME

## Fast and effortless screening for eye diseases in all care settings

### Why use artificial intelligence in screening?

- Artificial intelligence (AI) provides efficient processing for higher throughput
- AI detects early signs of retinal pathologies instantly and classifies the results according to severity
- AI allows ophthalmologists to focus on patients who are most in need of specialized care
- Our AI partner Thirona B.V. provides results that match the level of a professional human grader
- AI generates heatmaps as a supportive system for human experts to review and interpret visual indications

RetCAD™ Screening Report
RetCAD™

**Patient information**


Patient ID	qoV5P1D3gteb	Examination date	4--0-2023
Patient Name	-	Processing date	19-04-2023
Accession No.	-		

**Patient recommendation**


RetCAD™ outcome More than mild DR and suspicion of Glaucoma detected.	Recommendation Patient referral for follow-up testing is advised.
--	--

**OD**


RetCAD™ DR assessment: **Moderate DR detected**




RetCAD™ AMD assessment: **No AMD detected**



RetCAD™ GLC assessment: **Very suspicious of Glaucoma**




Exam quality: **good**




**OS**


RetCAD™ DR assessment: **Severe DR detected**




RetCAD™ AMD assessment: **No AMD detected**



RetCAD™ GLC assessment: **Very suspicious of Glaucoma**



Exam quality: **good**



**RetCAD™ score explanation**

<p><b>Diabetic Retinopathy (DR)</b> Relates to the ICDR* severity classification</p> <p>0: No DR detected 1: Mild DR detected 2: Moderate DR detected 3: Severe DR detected 4: Proliferative DR detected</p> <p><small>* International Clinical Diabetic Retinopathy</small></p>	<p><b>Age-related Macular Degeneration (AMD)</b> Relates to the AREDS* severity classification</p> <p>0: No AMD detected 1: Early AMD detected 2: Intermediate AMD detected 3: Advanced AMD detected**</p> <p><small>* Age-Related Eye Disease Study ** Advanced AMD includes both the wet and dry form</small></p>	<p><b>Glaucoma (GLC)</b> Indicates the likelihood for Glaucoma</p> <p>0: Not suspicious of glaucoma 1: Very suspicious of glaucoma</p>
--	---	--

**Disclaimers**  
When more than mild Diabetic Retinopathy (DR ≥ 2) or more than Early Age-related Macular Degeneration (AMD ≥ 2) or suspicion of Glaucoma (GLC ≥ 0.5) is detected, it is recommended to see an eye-care specialist for follow-up diagnosis. The RetCAD™ software is approved for clinical use and is CE (0344) certified as a Class IIa medical device. The analysis using RetCAD™ does not replace an eye-health check-up.

This report was generated using RetCAD™ v2.0.2, CE (0344), Thirona Retina

## The iCare Screening Solution allows **fast and effortless screening for diabetic retinopathy, AMD and glaucoma**


- High-quality images taken with iCare DRSplus\* meet the requirements of AI on the first take
- Swift, fully automated operations result in significant timesaving
- Dilation is not needed, and imaging is successful even in patients with media opacities
- More focused and controlled referral flow



## Enabling **digital screening pathways**

- Practice owners can offer screening as a new service
- Results can be stored in most widely used electronic health record systems, improving communication
- Referrals can be shared outside your organization, improving care compliance
- Data security and privacy meet the highest standards

## **Swift, fully automated** operations



1. The iCare DRSplus fundus imaging system is intuitive and requires minimal staff training.

2. High-quality images are automatically stored and forwarded for processing by AI.

3. The report is instantly available and can be discussed with the patient during the same visit.

\* iCare DRSplus fundus imaging system, using iCare TrueColor Confocal Technology

## iCare. For better perception.

iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Our devices cover automated fundus imaging systems, perimeters, and handheld rebound tonometers. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

We believe that ophthalmic care must be accessible, effortless, and reliable, and our aim is to establish the next level of eye care.

### **iCare World Australia**

Level 9, 276 Flinders Street  
Melbourne Victoria 3000,  
Australia  
Ph. +61 3 85927079  
infoAU@icare-world.com

### **Centervue S.p.A.**

Via San Marco 9H  
35129 Padova, Italy  
Ph. +39 049 501 8399  
info@icare-world.com

### **Icare Finland Oy**

Äyritie 22  
01510 Vantaa, Finland  
Ph. +358 9 8775 1150  
info@icare-world.com

### **Icare USA, Inc.**

4700 Falls of Neuse Rd. Ste 245  
Raleigh, NC. 27609  
Ph. +1 888.422.7313  
Fax +1 877.477.5485  
infoUSA@icare-world.com

[www.icare-world.com](http://www.icare-world.com)

**icare** For better perception

iCare is a trademark of Icare Finland Oy. Icare Finland Oy, Icare USA, Inc., iCare World Australia Pty Ltd and Centervue S.p.A., are parts of Revenio Group and represent the brand iCare. iCare ILLUME is a trademark or a registered trademark of Icare Finland Oy in the EU and the USA and/or other countries. Centervue S.P.A. is the legal manufacturer of DRSpplus. Not all products, accessories, services or offers are approved in every market. Approved labelling and instructions may vary from one country to another. This material is intended for healthcare professionals only. © 2023 Icare Finland Oy. All rights reserved.